Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

13.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

9.3K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
9.3K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

2.3K
2.3K
RNA Interference01:23

RNA Interference

24.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.2K
RNA Interference01:23

RNA Interference

6.4K
6.4K
Experimental RNAi02:15

Experimental RNAi

6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antisense Reduction of Mutant COMP Reduces Growth Plate Chondrocyte Pathology.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Naked antisense oligonucleotides remain endolysosomally sequestered despite induced membrane damage.

bioRxiv : the preprint server for biology·2026
Same author

Enhanced splicing modulation by NMA-modified antisense oligonucleotides.

Nucleic acids research·2026
Same author

Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of <i>HNRNPH2</i>-related neurodevelopmental disorder.

Science translational medicine·2026
Same author

Restoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy.

Nature communications·2026
Same author

Reduction of RAD23A extends lifespan and mitigates pathology in a mouse model of TDP-43 proteinopathy.

Nature communications·2026

Related Experiment Video

Updated: Apr 24, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

10.5K

Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.

Frank Rigo1, Punit P Seth, C Frank Bennett

  • 1Isis Pharmaceuticals, 2855 Gazelle Court, Carlsbad, CA, USA, FRigo@isisph.com.

Advances in Experimental Medicine and Biology
|September 10, 2014
PubMed
Summary

Antisense oligonucleotides (ASOs) offer a promising therapeutic strategy for diseases caused by messenger RNA (mRNA) processing defects. These agents precisely target RNA, correcting errors and modulating gene expression effectively.

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.5K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

18.4K

Related Experiment Videos

Last Updated: Apr 24, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

10.5K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.5K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

18.4K

Area of Science:

  • Molecular Biology
  • Genetics
  • RNA Biology

Background:

  • Pre-messenger RNA (pre-mRNA) undergoes crucial processing steps: capping, splicing, and polyadenylation, essential for protein translation.
  • Mutations in RNA sequences disrupting these processing steps are linked to various human diseases.
  • Conventional therapeutics struggle to address RNA-level defects effectively.

Purpose of the Study:

  • To review diverse antisense oligonucleotide (ASO)-based mechanisms for RNA expression modulation.
  • To discuss advancements in ASO medicinal chemistry and their pharmacokinetic/toxicological profiles.
  • To highlight the therapeutic potential of ASOs in treating pre-mRNA processing disorders.

Main Methods:

  • Review of scientific literature on antisense oligonucleotide (ASO) mechanisms.
  • Analysis of medicinal chemistry advancements in ASO development.
  • Examination of pharmacokinetic and toxicological data for ASOs.
  • Case studies of ASO applications in disease models.

Main Results:

  • ASOs can be designed to bind specific RNA transcripts via Watson-Crick base pairing.
  • Diverse ASO-based mechanisms exist for modulating RNA expression.
  • Medicinal chemistry and pharmacokinetic/toxicological understanding have advanced ASO therapeutic potential.
  • Successful preclinical application of ASOs in treating pre-mRNA processing diseases.

Conclusions:

  • ASOs represent an ideal therapeutic modality for diseases stemming from pre-mRNA processing defects.
  • Targeting RNA directly with ASOs offers a precise approach to disease correction.
  • Further development and understanding of ASOs promise significant clinical impact for genetic disorders.